カテゴリ： Transparency Market Research, 世界, 医療/バイオ

新型コロナウイルス感染症用ワクチンの世界市場（2022～2031）：ワクチン種類別

■ 英語タイトル：COVID-19 Vaccine Market (Vaccine Type: mRNA, Viral Vector Vaccines (Adenovirus Vaccines, Inactivated Virus Vaccines, and Others), and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

調査会社Transparency Market Research社が発行したリサーチレポート（データ管理コード：TMR23AP085）■ 発行会社/調査会社：Transparency Market Research
■ 商品コード：TMR23AP085
■ 発行日：2023年1月25日
■ 調査対象地域：グローバル
■ 産業分野：医療
■ ページ数：217
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後24時間以内）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧）USD5,795 ⇒換算￥880,840見積依頼/購入/質問フォーム
Multi User（5名様閲覧）USD8,795 ⇒換算￥1,336,840見積依頼/購入/質問フォーム
Corporate License（法人閲覧）USD11,795 ⇒換算￥1,792,840見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Transparency Market Research社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[新型コロナウイルス感染症用ワクチンの世界市場（2022～2031）：ワクチン種類別]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

Transparency Market Research社の本調査レポートでは、新型コロナウイルス感染症用ワクチンの世界市場について総合的に分析し、今後の市場動向を予測しています。本書は、序論、仮定＆調査手法、エグゼクティブサマリー、市場概要、市場動向、市場分析＆予測、ワクチン種類別（mRNA、ウイルスベクターワクチン、その他）分析、年齢層別（12歳~18歳、18歳以上）分析、流通チャンネル別（政府機関、病院＆クリニック、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などの項目が整理されています。また、本書内には、Pfizer-BioNTech、Moderna、AstraZeneca、Johnson & Johnson、Sinovac、Sinopharm、Bharat Biotech、Serum Institute of India、Novavax、Gamaleya Research Institute、CanSino Biologics、CureVac、GlaxoSmithKline、Sanofi-GSKなどの企業情報が含まれています。
・序論
・仮定＆調査手法
・エグゼクティブサマリー
・市場概要
・市場動向
・市場分析＆予測
・世界の新型コロナウイルス感染症用ワクチン市場規模：ワクチン種類別
- mRNAワクチンの市場規模
- ウイルスベクターワクチンの市場規模
- その他ワクチン種類の市場規模
・世界の新型コロナウイルス感染症用ワクチン市場規模：年齢層別
- 12歳~18歳用新型コロナウイルス感染症用ワクチンの市場規模
- 18歳以上用新型コロナウイルス感染症用ワクチンの市場規模
・世界の新型コロナウイルス感染症用ワクチン市場規模：流通チャンネル別
- 政府機関における市場規模
- 病院＆クリニックにおける市場規模
- その他における市場規模
・世界の新型コロナウイルス感染症用ワクチン市場規模：地域別
- 北米の新型コロナウイルス感染症用ワクチン市場規模
- ヨーロッパの新型コロナウイルス感染症用ワクチン市場規模
- アジア太平洋の新型コロナウイルス感染症用ワクチン市場規模
- 中南米のアルミニウムスラグ市場規模
- 中東・アフリカのアルミニウムスラグ市場規模
・競争状況

COVID-19 Vaccine Market – Scope of Report
TMR’s report on the global COVID-19 vaccine market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global COVID-19 vaccine market for the period 2017–2031, considering 2022 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global COVID-19 vaccine market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the COVID-19 vaccine market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global COVID-19 vaccine market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global COVID-19 vaccine market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global COVID-19 vaccine market.

The report delves into the competitive landscape of the global COVID-19 vaccine market. Key players operating in the global COVID-19 vaccine market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global COVID-19 vaccine market profiled in this report.

RESEARCH METHODOLOGY
The research methodology will be a combination of exhaustive primary and secondary research to analyze the market COVID-19 vaccine.

Secondary Research

Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.

Secondary research sources that we typically refer, but are not limited to:

Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market

Specific Secondary Sources:

• Industry Sources:
o WorldWideScience.org
o Elsevier, Inc.
o National Institutes of Health (NIH)
o PubMed
o NCBI
o Department of Health Care Service
• Trade Data Sources
o Trade Map
o UN Comtrade
o Trade Atlas
• Company Information
o OneSource Business Browser
o Hoover’s
o Factiva
o Bloomberg
• Mergers & Acquisitions
o Thomson Mergers & Acquisitions
o MergerStat
o Profound

Primary Research

During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.

We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:

Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies
Participants who typically take part in such a process include, but are not limited to:

Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals
List of primary participants, but not limited to:

Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.

Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.

Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:

Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities
Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global COVID-19 Vaccine Market
4. Market Overview
    4.1. Introduction
        4.1.1. COVID-19 vaccine Definition
        4.1.2. Industry Evolution/Developments
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global COVID-19 Vaccine Market Analysis and Forecast, 2017–2031
        4.4.1. Market Revenue Projections (US$ Mn)
5. Market Outlook
    5.1. Disease incidence and prevalence across the globe
    5.2. Analysis of COVID-19 vaccination across the globe
    5.3. Regulatory scenario across the globe/key countries
6. Global COVID-19 Vaccine Market Analysis and Forecast, by Vaccine Type
    6.1. Introduction & Definition
    6.2. Key Findings/Developments
    6.3. Market Value Forecast, by Vaccine Type, 2017–2031
        6.3.1. mRNA
        6.3.2. Viral Vector Vaccines
            6.3.2.1. Inactivated Virus Vaccines
            6.3.2.2. Adenovirus Vaccines
            6.3.2.3. Others
        6.3.3. Others
    6.4. Market Attractiveness, by Vaccine Type
7. Global COVID-19 Vaccine Market Analysis and Forecast, by Age Group
    7.1. Introduction & Definition
    7.2. Key Findings/Developments
    7.3. Market Value Forecast, by Age Group, 2017–2031
        7.3.1. 12 to 18
        7.3.2. Above 18
    7.4. Market Attractiveness, by Age Group
8. Global COVID-19 Vaccine Market Analysis and Forecast, by Distribution Channel
    8.1. Introduction & Definition
    8.2. Key Findings/Developments
    8.3. Market Value Forecast, by Distribution Channel, 2017–2031
        8.3.1. Government Entities
        8.3.2. Hospitals and Clinics
        8.3.3. Others
    8.4. Market Attractiveness, by Distribution Channel
9. Global COVID-19 Vaccine Market Analysis and Forecast, by Region
    9.1. Key Findings
    9.2. Market Value Forecast, by Region
        9.2.1. North America
        9.2.2. Europe
        9.2.3. Asia Pacific
        9.2.4. Latin America
        9.2.5. Middle East & Africa
    9.3. Market Attractiveness, by Country/Region
10. North America COVID-19 Vaccine Market Analysis and Forecast
    10.1. Introduction
        10.1.1. Key Findings
    10.2. Market Value Forecast, by Vaccine Type, 2017–2031
        10.2.1. mRNA
        10.2.2. Viral Vector Vaccines
            10.2.2.1. Inactivated Virus Vaccines
            10.2.2.2. Adenovirus Vaccines
            10.2.2.3. Others
        10.2.3. Others
    10.3. Market Value Forecast, by Age Group, 2017–2031
        10.3.1. 12 to 18
        10.3.2. Above 18
    10.4. Market Value Forecast, by Distribution Channel, 2017–2031
        10.4.1. Government Entities
        10.4.2. Hospitals and Clinics
        10.4.3. Others
    10.5. Market Value Forecast, by Country, 2017–2031
        10.5.1. U.S.
        10.5.2. Canada
    10.6. Market Attractiveness Analysis
        10.6.1. By Vaccine Type
        10.6.2. By Age Group
        10.6.3. By Distribution Channel
        10.6.4. By Country
11. Europe COVID-19 Vaccine Market Analysis and Forecast
    11.1. Introduction
        11.1.1. Key Findings
    11.2. Market Value Forecast, by Vaccine Type , 2017–2031
        11.2.1. mRNA
        11.2.2. Viral Vector Vaccines
            11.2.2.1. Viral Vector Vaccines
            11.2.2.2. Adenovirus Vaccines
            11.2.2.3. Others
        11.2.3. Others
    11.3. Market Value Forecast, by Age Group, 2017–2031
        11.3.1. 12 to 18
        11.3.2. Above 18
    11.4. Market Value Forecast, by Distribution Channel, 2017–2031
        11.4.1. Government Entities
        11.4.2. Hospitals and Clinics
        11.4.3. Others
    11.5. Market Value Forecast, by Country, 2017–2031
        11.5.1. U.K.
        11.5.2. Germany
        11.5.3. France
        11.5.4. Italy
        11.5.5. Spain
        11.5.6. Rest of Europe
    11.6. Market Attractiveness Analysis
        11.6.1. By Vaccine Type
        11.6.2. By Age Group
        11.6.3. By Distribution Channel
        11.6.4. By Country
12. Asia Pacific COVID-19 Vaccine Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast, by Vaccine Type, 2017–2031
        12.2.1. mRNA
        12.2.2. Viral Vector Vaccines
            12.2.2.1. Inactivated Virus Vaccines
            12.2.2.2. Adenovirus Vaccines
            12.2.2.3. Others
        12.2.3. Others
    12.3. Market Value Forecast, by Age Group, 2017–2031
        12.3.1. 12 to 18
        12.3.2. Above 18
    12.4. Market Value Forecast, by Distribution Channel, 2017–2031
        12.4.1. Government Entities
        12.4.2. Hospitals and Clinics
        12.4.3. Others
    12.5. Market Value Forecast, by Country, 2017–2031
        12.5.1. China
        12.5.2. Japan
        12.5.3. India
        12.5.4. Rest of Asia Pacific
    12.6. Market Attractiveness Analysis
        12.6.1. By Vaccine Type
        12.6.2. By Age Group
        12.6.3. By Distribution Channel
        12.6.4. By Country
13. Latin America COVID-19 Vaccine Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast, by Vaccine Type, 2017–2031
        13.2.1. mRNA
        13.2.2. Viral Vector Vaccines
            13.2.2.1. Inactivated Virus Vaccines
            13.2.2.2. Adenovirus Vaccines
            13.2.2.3. Others
        13.2.3. Others
    13.3. Market Value Forecast, by Age Group, 2017–2031
        13.3.1. 12 to 18
        13.3.2. Above 18
    13.4. Market Value Forecast, by Distribution Channel, 2017–2031
        13.4.1. Government Entities
        13.4.2. Hospitals and Clinics
        13.4.3. Others
    13.5. Market Value Forecast, by Country, 2017–2031
        13.5.1. Brazil
        13.5.2. Mexico
        13.5.3. Rest of Latin America
    13.6. Market Attractiveness Analysis
        13.6.1. By Vaccine Type
        13.6.2. By Age Group
        13.6.3. By Distribution Channel
        13.6.4. By Country
14. Middle East & Africa COVID-19 Vaccine Market Analysis and Forecast
    14.1. Introduction
        14.1.1. Key Findings
    14.2. Market Value Forecast, by Vaccine Type, 2017–2031
        14.2.1. mRNA
           14.2.1.1. Inactivated Virus Vaccines
           14.2.1.2. Adenovirus Vaccines
           14.2.1.3. Others
        14.2.2. Viral Vector Vaccines
        14.2.3. Others
    14.3. Market Value Forecast, by Age Group, 2017–2031
        14.3.1. 12 to 18
        14.3.2. Above 18
    14.4. Market Value Forecast, by Distribution Channel, 2017–2031
        14.4.1. Government Entities
        14.4.2. Hospitals and Clinics
        14.4.3. Others
    14.5. Market Value Forecast, by Country, 2017–2031
        14.5.1. GCC countries
        14.5.2. South Africa
        14.5.3. Rest of Middle East & Africa
    14.6. Market Attractiveness Analysis
        14.6.1. By Vaccine Type
        14.6.2. By Age Group
        14.6.3. By Distribution Channel
        14.6.4. By Country
15. Competition Landscape
    15.1. Market Player – Competition Matrix (by Tier and Size of Companies)
    15.2. Market Share Analysis by Company (2021)
    15.3. Company Profiles
        15.3.1. Pfizer-BioNTech
            15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.1.2. Vaccine Type Portfolio
            15.3.1.3. Financial Overview
            15.3.1.4. SWOT Analysis
            15.3.1.5. Strategic Overview
        15.3.2. Moderna
            15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.2.2. Vaccine Type Portfolio
            15.3.2.3. Financial Overview
            15.3.2.4. SWOT Analysis
            15.3.2.5. Strategic Overview
        15.3.3. AstraZeneca
            15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.3.2. Vaccine Type Portfolio
            15.3.3.3. Financial Overview
            15.3.3.4. SWOT Analysis
            15.3.3.5. Strategic Overview
        15.3.4. Johnson & Johnson
            15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.4.2. Vaccine Type Portfolio
            15.3.4.3. Financial Overview
            15.3.4.4. SWOT Analysis
            15.3.4.5. Strategic Overview
        15.3.5. Sinovac
            15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.5.2. Vaccine Type Portfolio
            15.3.5.3. Financial Overview
            15.3.5.4. SWOT Analysis
            15.3.5.5. Strategic Overview
        15.3.6. Sinopharm
            15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.6.2. Vaccine Type Portfolio
            15.3.6.3. Financial Overview
            15.3.6.4. SWOT Analysis
            15.3.6.5. Strategic Overview
        15.3.7. Bharat Biotech
            15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.7.2. Vaccine Type Portfolio
            15.3.7.3. Financial Overview
            15.3.7.4. SWOT Analysis
            15.3.7.5. Strategic Overview
        15.3.8. Serum Institute of India
            15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.8.2. Vaccine Type Portfolio
            15.3.8.3. Financial Overview
            15.3.8.4. SWOT Analysis
            15.3.8.5. Strategic Overview
        15.3.9. Novavax
            15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.9.2. Vaccine Type Portfolio
            15.3.9.3. Financial Overview
            15.3.9.4. SWOT Analysis
            15.3.9.5. Strategic Overview
        15.3.10. Gamaleya Research Institute
            15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.10.2. Vaccine Type Portfolio
            15.3.10.3. Financial Overview
            15.3.10.4. SWOT Analysis
            15.3.10.5. Strategic Overview
        15.3.11. CanSino Biologics
            15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.11.2. Vaccine Type Portfolio
            15.3.11.3. Financial Overview
            15.3.11.4. SWOT Analysis
            15.3.11.5. Strategic Overview
        15.3.12. CureVac
            15.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.12.2. Vaccine Type Portfolio
            15.3.12.3. Financial Overview
            15.3.12.4. SWOT Analysis
            15.3.12.5. Strategic Overview
        15.3.13. GlaxoSmithKline
            15.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.13.2. Vaccine Type Portfolio
            15.3.13.3. Financial Overview
            15.3.13.4. SWOT Analysis
            15.3.13.5. Strategic Overview
        15.3.14. Sanofi-GSK
            15.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.14.2. Vaccine Type Portfolio
            15.3.14.3. Financial Overview
            15.3.14.4. SWOT Analysis
            15.3.14.5. Strategic Overview

List of Tables

Table 01: Global COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Vaccine Type, 2017–2031

Table 02: Global COVID-19 Vaccine Market Value (US$ Mn) Forecast, by mRNA, 2017–2031

Table 03: Global COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Viral Vector Vaccines, 2017–2031

Table 04: Global COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Age Group, 2017–2031

Table 05: Global COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 06: Global COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 07: North America COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Vaccine Type, 2017–2031

Table 08: North America COVID-19 Vaccine Market Value (US$ Mn) Forecast, by mRNA, 2017–2031

Table 09: North America COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Viral Vector Vaccines, 2017–2031

Table 10: North America COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Age Group, 2017–2031

Table 11: North America COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 12: North America COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 13: Europe COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Vaccine Type , 2017–2031

Table 14: Europe COVID-19 Vaccine Market Value (US$ Mn) Forecast, by mRNA, 2017–2031

Table 15: Europe COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Viral Vector Vaccines, 2017–2031

Table 16: Europe COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Age Group, 2017–2031

Table 17: Europe COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 18: Europe COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017–2031

Table 19: Asia Pacific COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Vaccine Type, 2017–2031

Table 20: Asia Pacific COVID-19 Vaccine Market Value (US$ Mn) Forecast, by mRNA, 2017–2031

Table 21: Asia Pacific COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Viral Vector Vaccines, 2017–2031

Table 22: Asia Pacific COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Age Group, 2017–2031

Table 23: Asia Pacific COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 24: Asia Pacific COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017–2031

Table 25: Latin America COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Vaccine Type, 2017–2031

Table 26: Latin America COVID-19 Vaccine Market Value (US$ Mn) Forecast, by mRNA, 2017–2031

Table 27: Latin America COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Viral Vector Vaccines, 2017–2031

Table 28: Latin America COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Age Group, 2017–2031

Table 29: Latin America COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 30: Latin America COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017–2031

Table 31: Middle East & Africa COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Vaccine Type, 2017–2031

Table 32: Middle East & Africa COVID-19 Vaccine Market Value (US$ Mn) Forecast, by mRNA, 2017–2031

Table 33: Middle East & Africa COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Viral Vector Vaccines, 2017–2031

Table 34: Middle East & Africa COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Age Group, 2017–2031

Table 35: Middle East & Africa COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 36: Middle East & Africa COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017–2031

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 世界の新型インフルエンザワクチン市場予測2024年-2032年：ワクチン種類別（筋肉内、経鼻、皮内）、市場種類別（公的、民間）、地域別
  • 手動蘇生器の世界市場（2022～2031）：製品別
  • バッグバルブマスクの世界市場（2022～2031）：種類別、モダリティ別
  • ジェットネブライザーの世界市場（2022～2031）：製品別、用途別
  • 定量噴霧式吸入器の世界市場（2022～2031）：製品別、疾患別
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(TMR23AP085 )"新型コロナウイルス感染症用ワクチンの世界市場（2022～2031）：ワクチン種類別" (英文：COVID-19 Vaccine Market (Vaccine Type: mRNA, Viral Vector Vaccines (Adenovirus Vaccines, Inactivated Virus Vaccines, and Others), and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031)はTransparency Market Research社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。